List of Staxyn drug patents
Staxyn is owned by Bayer Hlthcare.
Staxyn contains Vardenafil Hydrochloride.
Staxyn has a total of 1 drug patent out of which 0 drug patents have expired.
Staxyn was authorised for market use on 17 June, 2010.
Staxyn is available in tablet, orally disintegrating;oral dosage forms.
The generics of Staxyn are possible to be released after 23 December, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8613950 | BAYER HLTHCARE | Pharmaceutical forms with improved pharmacokinetic properties |
Dec, 2028
(5 years from now) | |
Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2010
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
STAXYN family patents
3
United States
3
European Union
2
Malaysia
2
Russia
2
Costa Rica
2
Norway
2
Argentina
2
Peru
2
China
1
Portugal
1
Germany
1
Singapore
1
Uruguay
1
Guatemala
1
Spain
1
Brazil
1
Croatia
1
New Zealand
1
Dominican Republic
1
Austria
1
Mexico
1
Morocco
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
Honduras
1
Tunisia
1
South Africa
1
Japan
1
Canada
1
Cyprus
1
Slovenia
1
Ukraine
1
Israel
1
Poland
1
Australia
1
RS
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic